Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: VRTX

Vertex Pharmaceuticals Incorporated

Healthcare | Biotechnology
$556.75 as of 2026-09-03 10:21 UTC
Market Cap$141.4B
Volume1.73M
EPS (TTM)$15.32

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a $141.4B biotechnology company trading at $556.75 — 36.3× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-09-03 10:20 UTC.

52-Week Range
Low $412.27High $558.29

What Vertex Pharmaceuticals Incorporated does

Vertex Pharmaceuticals is a global biotechnology company that develops medicines for serious diseases, particularly in specialty markets. The company has approved medicines for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain, and is advancing multiple mid- and late-stage clinical programs across additional serious diseases including kidney diseases, neuropathic pain, type 1 diabetes, and myotonic dystrophy type 1.

Summarized from Vertex Pharmaceuticals Incorporated’s SEC filings · Read the filing ↗

Key facts

Quote
Price$556.75
Market cap$141.4B
Volume1.73M shares
52-week range$412.27 – $558.29
Valuation
P/E (TTM)36.34×
EV/EBITDA31.10×
EPS (TTM)$15.32
Price/book7.58×
Return on equity21.18%
Returns
52-week return+35.0%

Revenue, margins & earnings

FY2021 Net income: $2.34BFY2021 Taxes & interest: $440MFY2021 Operating costs: $4.79B$7.57BFY2021FY2022 Net income: $3.32BFY2022 Taxes & interest: $985MFY2022 Operating costs: $4.62B$8.93BFY2022FY2023 Net income: $3.62BFY2023 Taxes & interest: $212MFY2023 Operating costs: $6.04B$9.87BFY2023FY2024: net loss $536M on revenue $11.0B$11.0BFY2024FY2025 Net income: $3.95BFY2025 Taxes & interest: $220MFY2025 Operating costs: $7.83B$12.0BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-01
  • 2026-09-01Ambrose KristenSVP & Chief Accounting OfficerA5,000—
  • 2026-08-31SACHS BRUCE IG-6,000—
  • 2026-07-23Sachdev AmitEVP Chief Patient & Ext Af OffA8,251—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Vertex Pharmaceuticals Incorporated do?

Vertex Pharmaceuticals is a global biotechnology company that develops medicines for serious diseases, particularly in specialty markets.

What is VRTX's valuation?

VRTX trades at $556.75, 36.34× trailing earnings, 31.10× EV/EBITDA, as of 2026-09-03.

When did VRTX last file with the SEC?

Vertex Pharmaceuticals Incorporated's most recent SEC filing on record is a 8-K filed 2026-07-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-03 10:20 UTC. This page is also available as JSON at /api/data?ticker=VRTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for VRTX and 5,000+ tickers.

Create a free account — keep VRTX
For your agent
GET /api/data?ticker=VRTX

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt